| Literature DB >> 29644499 |
Craig Parkinson1, Kieran Foley2, Philip Whybra1, Robert Hills3, Ashley Roberts4, Chris Marshall5, John Staffurth6,7, Emiliano Spezi1,7.
Abstract
BACKGROUND: Prognosis in oesophageal cancer (OC) is poor. The 5-year overall survival (OS) rate is approximately 15%. Personalised medicine is hoped to increase the 5- and 10-year OS rates. Quantitative analysis of PET is gaining substantial interest in prognostic research but requires the accurate definition of the metabolic tumour volume. This study compares prognostic models developed in the same patient cohort using individual PET segmentation algorithms and assesses the impact on patient risk stratification. Consecutive patients (n = 427) with biopsy-proven OC were included in final analysis. All patients were staged with PET/CT between September 2010 and July 2016. Nine automatic PET segmentation methods were studied. All tumour contours were subjectively analysed for accuracy, and segmentation methods with < 90% accuracy were excluded. Standardised image features were calculated, and a series of prognostic models were developed using identical clinical data. The proportion of patients changing risk classification group were calculated.Entities:
Keywords: Automated segmentation; Esophageal cancer; PET/CT; Prognostic model
Year: 2018 PMID: 29644499 PMCID: PMC5895559 DOI: 10.1186/s13550-018-0379-3
Source DB: PubMed Journal: EJNMMI Res Impact factor: 3.138
Name and description of PET-AS methods used in this study, with references of published work using similar segmentation approaches
| Algorithm | Description | Key references |
|---|---|---|
| AT | 3D adaptive iterative thresholding, using background subtraction | Jentzen et al. [ |
| RG | 3D region-growing with automatic seed finder and stopping criterion | Day et al. [ |
| KM | 3D K-mean iterative clustering with custom stopping criterion | Zaidi and El Naqa [ |
| FCM | 3D fuzzy C-mean iterative clustering with custom stopping criterion | Belhassen and Zaidi [ |
| GCM | 3D Gaussian mixture models based clustering with custom stopping criterion | Hatt et al. [ |
| WT | Watershed transform-based algorithm, using sobel filter | Geets et al. [ |
Summary of quantitative imaging features
| Type/order of statistics | Feature | Brief definition |
|---|---|---|
| Morphological | Volume | Sum of voxels delineated multiplied by the volume of one voxel |
| Pre-discretisation | SUVmax | Maximum uptake of FDG in the MTV |
| Energy | Sum squared SUV values in the MTV | |
| First order | Skewness | Measures symmetry of intensity histogram |
| Kurtosis | Measures flatness of intensity histogram | |
| Entropy | Measures randomness | |
| Second order | Dissimilarity | Variation of grey level pairs (GLCM). Features were calculated for each unique direction and averaged with a distance setting of 1 |
| Higher order | Grey-level non-uniformity | Distribution of zone counts for each intensity value (GLSZM) |
| Zone percentage | Fraction of recorded zones compared to maximum possible | |
| Coarseness | Measures spatial rate of change in intensity using a distance of 1 |
Baseline characteristics of patient cohort
| Median age | 67.0 years (range 24–84) |
| Gender | Male 315 (73.8):female 112 (26.2) |
| Histology | |
| Adenocarcinoma | 313 (73.3) |
| Squamous cell carcinoma | 100 (23.4) |
| Undifferentiated | 5 (1.2) |
| High-grade dysplasia | 4 (0.9) |
| Neuro-endocrine | 3 (0.7) |
| Small cell carcinoma | 1 (0.2) |
| Sarcoma | 1 (0.2) |
| Tumour location | |
| Oesophagus | 268 (62.8) |
| Upper third | 14 (5.2) |
| Middle third | 71 (26.5) |
| Lower third | 183 (68.3) |
| Gastro-oesophageal junction | 159 (37.2) |
| Siewert I | 67 (42.1) |
| Siewert II | 42 (26.4) |
| Siewert III | 50 (31.4) |
| Stage group | |
| IA | 10 (2.3) |
| IB | 17 (4.0) |
| IIA | 70 (16.4) |
| IIB | 13 (3.0) |
| IIIA | 97 (22.7) |
| IIIB | 52 (12.2) |
| IIIC | 76 (17.8) |
| IV | 92 (21.5) |
| Treatment | |
| Curative | 224 (52.5) |
| NACT | 86 (38.4) |
| dCRT | 86 (38.4) |
| Surgery alone | 31 (13.8) |
| NACRT | 20 (8.9) |
| EMR | 1 (0.5) |
| Palliative | 203 (47.5) |
| Mortality | |
| Alive | 132 (30.9) |
| Dead | 295 (69.1) |
Final output of prognostic models derived using AT, GCM3, KM2 and WT PET segmentation methods
| Parameter estimate | Hazard ratio | 95% CI | ||
|---|---|---|---|---|
| AT | ||||
| Age | 0.020 | 0.001 | 1.020 | 1.008–1.033 |
| Treatment | − 1.075 | < 0.001 | 0.341 | 0.254–0.459 |
| Stage | 0.144 | < 0.001 | 1.155 | 1.072–1.245 |
| GCM3 | ||||
| Age | 0.019 | 0.003 | 1.019 | 1.006–1.032 |
| Treatment | − 1.024 | < 0.001 | 0.359 | 0.266–0.485 |
| Stage | 0.142 | < 0.001 | 1.153 | 1.068–1.245 |
| Kurtosis | 0.632 | 0.002 | 1.882 | 1.260–2.809 |
| Skewness | − 0.789 | 0.044 | 0.454 | 0.211–0.980 |
| KM2 | ||||
| Age | 0.020 | 0.001 | 1.020 | 1.008–1.033 |
| Treatment | − 1.075 | < 0.001 | 0.341 | 0.254–0.459 |
| Stage | 0.144 | < 0.001 | 1.155 | 1.072–1.245 |
| WT | ||||
| Age | 0.018 | 0.004 | 1.018 | 1.006–1.031 |
| Treatment | − 1.063 | < 0.001 | 0.345 | 0.257–0.464 |
| Stage | 0.140 | < 0.001 | 1.150 | 1.065–1.242 |
| GLNU | 0.017 | 0.006 | 1.017 | 1.005–1.029 |
| Skewness | 0.674 | 0.030 | 1.962 | 1.067–3.607 |
Prognostic model equations
| Segmentation Method | Prognostic model equation |
|---|---|
| AT | (Age × 0.020 − (Treatment × 1.075) + (Stage × 0.144) |
| GCM3 | (Age × 0.019) − (Treatment × 1.024) + (Stage × 0.142) − (Skewness × 0.789) + (Kurtosis × 0.632) |
| KM2 | (Age × 0.020) − (Treatment × 1.075) + (Stage × 0.144) |
| WT | (Age × 0.018) − (Treatment × 1.063) + (Stage × 0.140) + (Skewness × 0.674) + (GLNU × 0.017) |
Fig. 1Risk stratification and OS for WT (top left), KM2 (top right), AT (bottom left) GCM3 (bottom right)
Number of patients in each risk stratification group for each single prognostic model and prognostic score range
| Number of patients in risk group (prognostic range) | Low-risk | Intermediate-risk | High-risk |
|---|---|---|---|
| AT/KM2 | 141 (− 0.45–0.98) | 143 (0.99–2.16) | 143 (2.17–2.79) |
| GCM3 | 140 (− 1.13–0.36) | 143 (0.37–1.54) | 144 (1.55–2.73) |
| WT | 142 (−0.17–1.30) | 144 (1.31–2.48) | 141 (2.49–3.62) |
Total number of patients and percentage that change risk-stratification group
| Number changing group (%) | AT | GCM3 | KM2 | WT |
|---|---|---|---|---|
| AT | ||||
| GCM3 | 66 (15.4) | |||
| KM2 | 0 (0.0) | 66 (15.4) | ||
| WT | 57 (13.3) | 73 (17.1) | 57 (13.3) |